Use of proteomic patterns in serum to identify ovarian cancer

被引:2554
作者
Petricoin, EF
Ardekani, AM
Hitt, BA
Levine, PJ
Fusaro, VA
Steinberg, SM
Mills, GB
Simone, C
Fishman, DA
Kohn, EC
Liotta, LA
机构
[1] US FDA, Natl Inst Hlth Clin Proteom Program, Dept Therapeut Prot, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA
[2] NCI, Biostat & Data Management Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] Correlog Syst Inc, Bethesda, MD USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Div Canc Med, Houston, TX 77030 USA
[5] Simone Protect Canc Inst, Lawrenceville, NJ USA
[6] Northwestern Univ, Sch Med, Natl Ovarian Canc Early Detect Program, Chicago, IL USA
关键词
D O I
10.1016/S0140-6736(02)07746-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background New technologies for the detection of early-stage ovarian cancer are urgently needed. Pathological changes within an organ might be reflected in proteomic patterns in serum. We developed a bioinformatics tool and used it to identify proteomic patterns in serum that distinguish neoplastic from non-neoplastic disease within the ovary. Methods Proteomic spectra were generated by mass spectroscopy (surface-enhanced laser desorption and ionisation). A preliminary "training" set of spectra derived from analysis of serum from 50 unaffected women and 50 patients with ovarian cancer were analysed by an iterative searching algorithm that identified a proteomic pattern that completely discriminated cancer from non-cancer. The discovered pattern was then used to classify an independent set of 116 masked serum samples: 50 from women with ovarian cancer, and 66 from unaffected women or those with non-malignant disorders. Findings The algorithm identified a cluster pattern that, in the training set, completely segregated cancer from non-cancer. The discriminatory pattern correctly identified all 50 ovarian cancer cases in the masked set, including all 18 stage I cases. Of the 66 cases of non-malignant disease, 63 were recognised as not cancer. This result yielded a sensitivity of 100% (95% CI 93-100), specificity of 95% (87-99), and positive predictive, value of 94% (84-99). Interpretation These findings justify a prospective population-based assessment of proteomic pattern technology as a screening tool for all stages of ovarian cancer in high-risk and general populations.
引用
收藏
页码:572 / 577
页数:6
相关论文
共 21 条
  • [1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [2] [Anonymous], NONPARAMETRIC STAT M
  • [3] TESTS FOR LINEAR TRENDS IN PROPORTIONS AND FREQUENCIES
    ARMITAGE, P
    [J]. BIOMETRICS, 1955, 11 (03) : 375 - 386
  • [4] A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER
    BAST, RC
    KLUG, TL
    STJOHN, E
    JENISON, E
    NILOFF, JM
    LAZARUS, H
    BERKOWITZ, RS
    LEAVITT, T
    GRIFFITHS, CT
    PARKER, L
    ZURAWSKI, VR
    KNAPP, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) : 883 - 887
  • [5] SOME METHODS FOR STRENGTHENING THE COMMON X2 TESTS
    COCHRAN, WG
    [J]. BIOMETRICS, 1954, 10 (04) : 417 - 451
  • [6] Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction
    Cohen, LS
    Escobar, PF
    Scharm, C
    Glimco, B
    Fishman, DA
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 82 (01) : 40 - 48
  • [7] Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
    Golub, TR
    Slonim, DK
    Tamayo, P
    Huard, C
    Gaasenbeek, M
    Mesirov, JP
    Coller, H
    Loh, ML
    Downing, JR
    Caligiuri, MA
    Bloomfield, CD
    Lander, ES
    [J]. SCIENCE, 1999, 286 (5439) : 531 - 537
  • [8] Herbert B.R., 1997, PROTEOME RES NEW FRO, P13
  • [9] HOLLAND JH, 1994, ADAPTATION NATURAL A
  • [10] Screening for ovarian cancer: a pilot randomised controlled trial
    Jacobs, IJ
    Skates, SJ
    MacDonald, N
    Menon, U
    Rosenthal, AN
    Davies, AP
    Woolas, R
    Jeyarajah, AR
    Sibley, K
    Lowe, DG
    Oram, DH
    [J]. LANCET, 1999, 353 (9160) : 1207 - 1210